PCVX
VENTE TOTALE: 60 896 titres (~3 285 572,26 $ US)
- Insiders
- PICKERING GRANT
- Total bought
- —
- Total sold
- $3,285,572
- Last activity
- 2026-07-27
- Last synced
-
2026-08-02 18:09:48
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-02
PCVX's adequate liquidity (score: 75) is structurally necessary for a pre-revenue biotech and does not offset its deeply weak fundamentals (score: 15), characterized by zero revenue, persistent cash burn, and negative…
The first sentence of the analysis written for PCVX on 2026-08-02 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 7.909 | 12.755 | 7.541 | 23.259 | 8.927 | |
| Quick Ratio | 7.909 | 12.755 | 7.541 | 23.259 | 8.927 | |
| Solvency Ratio | -2.058 | -2.180 | -2.342 | -4.072 | -2.396 | |
| Cash Ratio | 0.845 | 2.767 | 2.735 | 20.596 | 2.402 | |
| Price To Earnings Ratio | -8.195 | -21.542 | -15.169 | -13.939 | -12.326 | |
| Price To Earnings Growth Ratio | -0.170 | 2.623 | -0.745 | -0.178 | 0.352 | |
| Forward Price To Earnings Growth Ratio | -0.170 | 2.623 | -0.745 | -0.178 | 0.352 | |
| Price To Earnings Diluted Ratio | -8.195 | -21.542 | -15.169 | -13.939 | -12.326 | |
| Price To Earnings Diluted Growth Ratio | -0.170 | 2.623 | -0.745 | -0.178 | 0.352 | |
| Price To Book Ratio | 2.338 | 3.021 | 4.919 | 3.262 | 4.349 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -9.382 | -21.022 | -16.732 | -17.632 | -9.654 | |
| Price To Operating Cash Flow Ratio | -9.578 | -22.064 | -20.558 | -18.235 | -10.175 | |
| Debt To Assets Ratio | 0.075 | 0.020 | 0.021 | 0.018 | 0.052 | |
| Debt To Equity Ratio | 0.085 | 0.022 | 0.024 | 0.019 | 0.059 | |
| Debt To Capital Ratio | 0.079 | 0.021 | 0.023 | 0.018 | 0.056 | |
| Long Term Debt To Capital Ratio | 0.040 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.134 | 1.062 | 1.135 | 1.055 | 1.142 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.186 | -3.229 | -2.042 | -4.210 | -4.227 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.021 | 1.050 | 1.229 | 1.034 | 1.054 | |
| Debt Service Coverage Ratio | -121.125 | 0.000 | 0.000 | -107,015.000 | -13,801.857 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -116,128.000 | -14,810.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -107.050 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2.865 | -6.365 | -10.156 | -9.509 | -7.233 | |
| Capital Expenditure Coverage Ratio | -47.807 | -20.182 | -4.372 | -29.207 | -18.519 | |
| Dividend Paid And Capex Coverage Ratio | -47.807 | -20.182 | -4.372 | -29.207 | -18.519 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -8.539 | -21.581 | -14.622 | -10.719 | -12.245 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 7.909 | ▼-4.846 | ▼-4.169 |
| Quick Ratio | 7.909 | ▼-4.846 | ▼-4.169 |
| Solvency Ratio | -2.058 | ▲0.123 | ▲0.552 |
| Cash Ratio | 0.846 | ▼-1.921 | ▼-5.024 |
| Price To Earnings Ratio | -8.195 | ▲13.347 | ▲6.039 |
| Price To Earnings Growth Ratio | -0.170 | ▼-2.793 | ▼-0.546 |
| Forward Price To Earnings Growth Ratio | -0.170 | ▼-2.793 | ▼-0.546 |
| Price To Earnings Diluted Ratio | -8.195 | ▲13.347 | ▲6.039 |
| Price To Earnings Diluted Growth Ratio | -0.170 | ▼-2.793 | ▼-0.546 |
| Price To Book Ratio | 2.338 | ▼-0.683 | ▼-1.240 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -9.382 | ▲11.640 | ▲5.503 |
| Price To Operating Cash Flow Ratio | -9.578 | ▲12.486 | ▲6.544 |
| Debt To Assets Ratio | 0.075 | ▲0.055 | ▲0.038 |
| Debt To Equity Ratio | 0.085 | ▲0.064 | ▲0.044 |
| Debt To Capital Ratio | 0.079 | ▲0.058 | ▲0.039 |
| Long Term Debt To Capital Ratio | 0.040 | ▲0.040 | ▲0.032 |
| Financial Leverage Ratio | 1.134 | ▲0.072 | ▲0.029 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -3.186 | ▲0.043 | ▲0.193 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.021 | ▼-0.029 | ▼-0.057 |
| Debt Service Coverage Ratio | -121.125 | ▼-121.125 | ▲24066.472 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲26187.600 |
| Short Term Operating Cash Flow Coverage Ratio | -107.050 | ▼-107.050 | ▼-85.640 |
| Operating Cash Flow Coverage Ratio | -2.865 | ▲3.500 | ▲4.361 |
| Capital Expenditure Coverage Ratio | -47.807 | ▼-27.625 | ▼-23.789 |
| Dividend Paid And Capex Coverage Ratio | -47.807 | ▼-27.625 | ▼-23.789 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -8.539 | ▲13.042 | ▲5.002 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.28B | $9.99B | $6.10B | $3.11B | $1.24B | |
| Enterprise value | $6.33B | $9.67B | $5.73B | $2.29B | $1.18B | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -9.66x | -21.36x | -19.32x | -13.45x | -9.74x | |
| EV / Free cash flow | -9.46x | -20.36x | -15.72x | -13.00x | -9.25x | |
| EV / EBITDA | -8.54x | -21.58x | -14.62x | -10.72x | -12.24x | |
| Net debt / EBITDA | -0.07x | 0.71x | 0.94x | 3.82x | 0.54x | |
| Current ratio | 7.91x | 12.76x | 7.54x | 23.26x | 8.93x | |
| Income quality | 0.85x | 0.98x | 0.74x | 0.76x | 1.21x | |
| Graham net-net | $9 | $13 | $9 | $14 | $4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $1.42B | $1.65B | $950.6M | $902.0M | $227.6M | |
| Invested capital | $1.91B | $1.92B | $1.06B | $933.7M | $263.5M | |
| Return on assets | -25.2% | -13.2% | -28.6% | -22.2% | -30.9% | |
| Operating ROA | -28.2% | -23.2% | -38.8% | -34.9% | -28.9% | |
| Return on tangible assets | -25.2% | -13.2% | -28.6% | -22.2% | -30.9% | |
| Return on equity | -28.5% | -14.0% | -32.4% | -23.4% | -35.2% | |
| Return on invested capital | -32.5% | -16.9% | -36.9% | -23.9% | -34.5% | |
| Return on capital employed | -32.5% | -16.9% | -37.1% | -24.1% | -35.1% | |
| Earnings yield | -12.2% | -4.6% | -6.6% | -7.2% | -8.1% | |
| Free cash flow yield | -10.7% | -4.8% | -6.0% | -5.7% | -10.4% | |
| Capex / Op. cash flow | -2.1% | -5.0% | -22.9% | -3.4% | -5.4% | |
| Capex / Depreciation | 55.2% | 141.5% | 667.4% | 61.8% | 189.6% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-37.1%EV / Sales n/aEV / EBITDA ▲+60.4%EV / Op. cash flow ▲+11.702Earnings yield ▼-0.076
Profitability
Return on equity ▼-0.145Return on assets ▼-0.120Return on invested capital ▼-0.156Return on capital employed ▼-0.156Operating ROA ▼-0.050Income quality ▼-0.120Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-4.846Net debt / EBITDA ▼-0.781Working capital ▼-226194000.000Invested capital ▼-4623000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+408.3%EV / Sales n/aEV / EBITDA ▲+30.3%EV / Op. cash flow ▲+0.084Earnings yield ▼-0.041
Profitability
Return on equity ▲+0.067Return on assets ▲+0.057Return on invested capital ▲+0.020Return on capital employed ▲+0.025Operating ROA ▲+0.007Income quality ▼-0.358Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-1.018Net debt / EBITDA ▼-0.614Working capital ▲+1193979000.000Invested capital ▲+1649785000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-13 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-05-12 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2022-12-12 | Christopher L. Jacobs | Sale (Full) | $1,001 - $15,000 |
| 2022-11-08 | Christopher L. Jacobs | Purchase | $1,001 - $15,000 |
Recent news
- 2026-07-28 Bank of New York Mellon Corp Has $27.57 Million Stock Holdings in Vaxcyte, Inc. $PCVX Bank of New York Mellon Corp lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 5.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 474,526 shares of the company's stock after purchasing an additional 25,163
- 2026-07-08 Vaxcyte to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:
- 2026-06-02 Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus
- 2026-05-12 Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- 2026-05-06 Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
- 2026-05-01 Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market Vaxcyte is evolving from a single-product biotech into a commercial vaccine platform with advanced manufacturing and regulatory alignment. VAX-31, a 31-valent pneumococcal conjugate vaccine, targets broader serotype coverage than competitors and is in pivotal Phase 3 adult and Phase 2 infant trials. PCVX boasts strong financials, with over $2.4B in cash and a completed manufacturing facility, enabling concurrent late-stage development and commercial preparation.